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Background
In vitro assessment of HIV neutralization for pathogenesis
or vaccine efficacy studies is a complex task, attributable
to several confounding variables surrounding virus, anti-
bodies and host cells employed. NeutNet, a collaboration
involving 18 independent laboratories from 12 countries,
showed during the first phase clear differences in neutral-
ization assay sensitivity that were dependent on both the
antibody (TriMab, 4E10, sCD4) and the virus used http:/
/www.PlosOne.org. The second phase of NeutNet focused
on testing polyclonal reagents against a panel of viruses
with 17 different assays.
Methods
Each laboratory evaluated TriMab, 8 HIV-positive and one
seronegative sera at a given range of dilutions against 8
viruses representing different subtypes and phenotypes
with 17 different assays. Assays utilized uncloned virus
supernatant (virus infectivity assays-VIA) or Env-pseudo-
typed viruses (PSV assays). Target cells included PBMCs
and engineered cell lines in a single- or multiple-cycle
infection format. A range of read-outs were used, which
included intra- and extra-cellular p24 detection, and luci-
ferase or beta-galactosidase reporter gene expression.
Results
Neutralization with TriMab showed variation for both
PSV and VI assays when comparing results of phase I and
II. Negative serum gave sporadic neutralization in both
types of assays only when the inhibitory concentration
(IC) 50 was considered. IC50 showed more variation than
IC 75 and 90 for PBMC-based VIA. PSV assays were in gen-
eral not more sensitive than VIA. Variation was dependent
on both sera and viruses used. Specific assay to assay com-
parison showed impact of the target cell used.
Conclusion
In agreement with our phase I observations, we here
observed that also for polyclonal agents, the assay condi-
tions seem to influence the outcome of HIV-1 neutraliza-
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tion in vitro. Since protective neutralizing immunity in vivo
is not yet defined, no single assay can be recommended to
achieve optimal information on the neutralization poten-
tial of a serum or agent.